+1 Recommend
1 collections
      • Record: found
      • Abstract: found
      • Article: found

      Correlation of Muscarinic Receptor Induction in the Ventromedial Hypothalamic Nucleus with the Activation of Feminine Sexual Behavior by Estradiol

      Read this article at

          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.


          The administration of the steroid hormone, 17β-estradiol (E<sub>2</sub>) to ovariectomized rats increases the levels of muscarinic cholinergic receptors by 20–40% in the hypothalamic area. Using microdissection techniques, this increase has been shown to occur in hypothalamic subregions that possess high levels of intracellular receptors for E<sub>2</sub>. Among these regions is the ventromedial nucleus (VMN), which may be the principal target site in the rat brain for the activation of feminine sexual behavior by E<sub>2</sub>. In this study, we have further characterized the increase in muscarinic binding within the VMN after E<sub>2</sub> and show that it satisfies many of the criteria for an important regulatory mechanism by which E<sub>2</sub> could activate sexual behavior: (1) Using quantitative receptor autoradiography, it was determined that the increase in [<sup>3</sup>H]-QNB binding in the VMN after E<sub>2</sub> results from an increase in the number of receptors rather than a change in the affinity of the binding. (2) The increase in VMN muscarinic receptors as determined by the binding of [<sup>3</sup>H]-QNB to microdissected homogenates occurred by 18–24 h after exposure to E<sub>2</sub>, the earliest time at which sexual behavior is facilitated. (3) Increased muscarinic receptors did not occur in the VMN of male rats, which show little activation of feminine sexual behavior after E<sub>2</sub> exposure. (4) Muscarinic receptors in the VMN of female rats are induced at 24 h by a 6 h exposure to E<sub>2</sub>, the minimum length of time that is sufficient for E<sub>2</sub> to activate sexual behavior. A 4 h exposure to E<sub>2</sub> is insufficient to activate both sexual behavior and induce muscarinic receptors. (5) Administration of the protein synthesis inhibitor, anisomycin, during the 6 h E<sub>2</sub> exposure will block both the increase in muscarinic receptor levels and the activation of feminine sexual behavior. These results are consistent with the notion that the muscarinic cholinergic receptor may be one of the proteins induced by E<sub>2</sub> in the VMN to activate sexual behavior.

          Related collections

          Author and article information

          S. Karger AG
          28 March 2008
          : 39
          : 5
          : 476-480
          Department of Pharmacology/G3, Medical School, University of Pennsylvania, Philadelphia, Pa., and Rockefeller University, New York, N.Y., USA
          124044 Neuroendocrinology 1984;39:476–480
          © 1984 S. Karger AG, Basel

          Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher. Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

          Page count
          Pages: 5
          Original Paper


          Comment on this article